Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.43 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.33 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.33 |
| ▸ | CLK1 | P49759 | 1/20 | 0.33 |
| ▸ | CLK2 | P49760 | 1/20 | 0.33 |
| ▸ | CLK3 | P49761 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | DYRK4 | Q9NR20 | 1/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2124381 | 1.00 | TRPM8 (0.46) | TRPM8TRPA1EPHX1KCNA5ALDH1A1 | |
| SCHEMBL27768720 | 0.81 | TRPM8 (0.46) | TRPM8TRPA1EPHX1KCNA5ALDH1A1 | |
| SCHEMBL7625200 | 0.81 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL19636145 | 0.79 | TRPM8 (0.50) | TRPM8TRPA1EPHX1KCNA5ALDH1A1 | |
| SCHEMBL25921899 | 0.79 | TRPM8 (0.50) | TRPM8TRPA1EPHX1KCNA5ALDH1A1 | |
| SCHEMBL48381 | 0.78 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL10536020 | 0.78 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL9059955 | 0.76 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL8339136 | 0.72 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL1603520 | 0.71 | TRPM8 (0.50) | TRPM8TRPA1EPHX1KCNA5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150266810-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | V-BAC HOLDING CORP. (CA) | 2015-09-24 | — | — | US | disclosed |
| US-20150266810-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | V-BAC HOLDING CORP. (CA) | 2015-09-24 | — | — | US | disclosed |
| US-20130190296-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190296-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2013-07-25 | — | — | US | disclosed |
| US-8389730-B2 | Compositions and methods for the treatment of disease associated with TRP-P8 expression | DENDREON CORPORATION (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389730-B2 | Compositions and methods for the treatment of disease associated with TRP-P8 expression | DENDREON CORPORATION (US) | 2013-03-05 | — | — | US | disclosed |
| US-8362264-B2 | Tryptophan antagonist; anticancer agents | DENDREON CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362264-B2 | Tryptophan antagonist; anticancer agents | DENDREON CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190296-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | TRPC4, TRPC3, TRPC1 | TRPM8 10/4885TRPA1 46/4885EPHX1 2902/4885 |
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | TRPC4, TRPC3, TRPC1 | TRPM8 8/4885TRPA1 31/4885EPHX1 2270/4885 |
| US-20150266810-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | TRPC4, TRPC3, TRPC1 | TRPM8 11/4885TRPA1 69/4885EPHX1 3082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.